Skip to main content
. Author manuscript; available in PMC: 2010 Sep 2.
Published in final edited form as: Vaccine. 2009 Apr 19;27(27):3513–3518. doi: 10.1016/j.vaccine.2009.03.089

Figure 4.

Figure 4

Survival studies of BALB/c mice lethally infected with C. neoformans ATCC 24067. (Panel A) MAbs 1H1 (IgA), 5H8 (IgM), 3F10 (IgM), 1D6 (IgM), and 1E3 (IgM) were each administered 30 minutes prior to infection with 106 yeast cells. By intraperitoneal injection. NSO ascites generated from the nonproducing hybridoma partner, was used as a control. (Panel B). Survival of mice immunized with M2-HSA (10 ug/ml), HSA (10 ug/ml), or PBS and then challenged with C. neoformans (Panel B). Mice were immunized three times prior to infection with 6 × 105 yeast cells. In panels A and B, mice were infected with C. neoformans intravenously.